AI Article Synopsis
- Graves' Disease (GD) is an autoimmune disorder more common in women, and a study examined the levels of estrogen and progesterone receptors as well as cell proliferation in thyroid tissues from GD and nodular goiter (NG) patients.
- Significant findings showed that GD patients had higher progesterone receptor expression and Ki-67 proliferation index compared to NG patients, indicating more active cell growth in GD.
- However, no significant correlations were found with patient demographics or disease markers, suggesting that hormonal receptor levels in the thyroid do not differ significantly between male and female patients with GD.
Article Abstract
Graves' Disease (GD) is an autoimmune disease with higher prevalence in women than in men. The aim of the study was to correlate the expression of estrogen (ER) and progesterone receptors (PR) as well as Ki- 67 cell proliferation index in thyroid sections of GD and nodular goiter (ND) patients. The study was performed on archival paraffin blocks of 77 GD and 25 ND patients using immunohistochemistry. Higher expression of progesterone receptors (p = 0.0276) and Ki-67 index (p < 0.0001) was observed in thyroids of GD as compared to NG patients. No correlations were found between the particular markers and patients' clinicopathological parameters, sex or age. A higher incidence of GD in women was not associated with different thyroid expression of ER and PR in comparison to men. No correlation was found between the expression of ER and PR and proliferation marker of thyrocytes of GD and ND patients. Significantly higher expression of the Ki-67 antigen in GD lesions was observed as compared to the NG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5603/FHC.2013.0021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of polygenic risk scores for hormones and receptors levels in patients with vestibulodynia: a case-control study.
J Sex Med
January 2025
Clinical Obstetric and Gynecological V Buzzi, ASST-FBF-Sacco, Via Castelvetro 24-20124-University of the Study of Milan, Milan, Italy.
Background: Vulvodynia is a multifactorial disease affecting 7%-16% of reproductive-aged women in general population; however, little is still known about the genetics underlying this complex disease.
Aim: To compare polygenic risk scores for hormones and receptors levels in a case-control study to investigate their role in vulvodynia and their correlation with clinical phenotypes.
Methods: Our case-control study included patients with vestibulodynia (VBD) and healthy women.
Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer.
Cancers (Basel)
January 2025
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Background: Proteasomes degrade intracellular proteins. Different proteasome forms were identified. Proteasome inhibitors are used in cancer therapy, and novel drugs directed to specific proteasome forms are developed.
View Article and Find Full Text PDFExploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization.
Diagn Pathol
January 2025
Pathology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan, 430022, Hubei Province, China.
Breast cancer became the most prevalent malignancy among women, and HER2 expression status is critical for treatment decisions. With the emergence of ADC drugs, HER2 low-expressing patients who previously did not respond well to traditional anti-HER2 therapies may now benefit. In this study, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were applied to assess HER2 expression in 349 patients with HER2-non-positive breast cancer.
View Article and Find Full Text PDFDevelopment and validation of a metabolic syndrome and its components to predict the efficacy of neoadjuvant chemotherapy in breast cancer: An observational, single-center, cohort study.
Medicine (Baltimore)
January 2025
Department of Thyroid and Breast Surgery, Hebei General Hospital, Shijiazhuang, Hebei Province, China.
To assess whether metabolic syndrome can be used as a reference index to evaluate the efficacy of neoadjuvant chemotherapy treatment for breast cancer (BC). Seventy cases of female BC patients who received neoadjuvant chemotherapy treatment and surgical treatment at the Glandular Surgery Department of Hebei Provincial People's Hospital from January 2021 to December 2023 were retrospectively collected, and clinical data such as puncture pathology were recorded. The clinical data were analyzed by 1-way analysis using the χ2 test, and further multifactorial logistic regression analysis was performed for statistically significant differences.
View Article and Find Full Text PDFAmpligo® 150 ZC affect the expression of sex hormone receptors and cell proliferation marker in female rabbit ovary: Protective effects of thyme essential oil and vitamin C.
Reprod Toxicol
January 2025
Natural Resources Laboratory, University Mouloud Mammeri, BP 15017. Tizi-Ouzou. Algeria.
Pesticides tend to cause serious reproductive defects, disturbing endocrine functions and reducing fertility, especially in females. The objective of this work was to identify the reprotoxic effects of Ampligo® 150 ZC (AP), a mixture formulation of lambda cyhalothrin and chlorantraniliprole, on the ovary of female rabbits (Oryctolagus cuniculus) and the possible protective effect of co-treatment with thyme essential oil (TEO), extracted from (Thymus vulgaris) species, and vitamin C (vit C). Twenty female rabbits were divided into four equal groups (n=5): Control (distilled water), AP (20mg/ kg bw of the insecticide mixture every other day, by gavage for 28 days), AP+TEO (20mg/ kg bw of AP + 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!